We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

Competition Bureau reaches agreement in TevaRatiopharm merger

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • August 25 2010

On July 30, 2010, the Competition Bureau (Bureau) announced that it had reached a consent agreement with Teva Pharmaceuticals Industries Ltd. (Teva) and the Merckle Group, carrying on business as ratiopharm, requiring the divestiture of assets and associated licenses in relation to certain forms of acetaminophen oxycodone tablets and morphine sulfate sustained release tablets

Akzo Nobel fined $3.15 million for price fixing

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • November 24 2008

Canada's Competition Bureau announced on November 21, 2008 that Akzo Nobel Chemicals International BV had pled guilty to criminal charges for fixing the price of hydrogen peroxide sold in Canada between 1998 and 2001, and agreed to pay a C$3

Health and environmental claims an ongoing bureau focus

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work

Bureau releases generic drug sector study

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • November 15 2007

On October 29, 2007 the Competition Bureau (the Bureau) released its Canadian Generic Drug Sector Study, initiated in September, 2006, to identify areas where changes in the market framework might attain greater benefits through competition